文献速递腹部技术与安全CTMRPET

新辅助治疗后胰腺癌可切除性的影像学评估:AJR专家小组叙述性综述

Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: AJR Expert Panel Narrative Review.
PubMed 文献 · AJR Am J Roentgenol · 2021-12-01

本文为AJR专家小组叙述性综述,更新新辅助治疗(NAT)后胰腺导管腺癌(PDAC)可切除性的影像学评估。文章描述临界可切除PDAC的当前定义、NAT获益判断意义,讨论影像区分NAT后缓解与稳定或进展疾病的特定局限(包括方案优化、肿瘤大小评估、血管评估和肝转移检测),考虑MRI及PET/杂交成像的作用,并提供NAT后使用的简短PDAC报告模板。

要点

  • 当前影像技术无法可靠区分NAT后治疗缓解与稳定或进展疾病。
  • 综述涵盖NAT后PDAC可切除性评估的方案优化、肿瘤大小、血管评估及肝转移检测局限。
  • 文末提供NAT后使用的简短PDAC报告模板以改进放射科医生评估。

核心结论

  • 当前影像技术无法可靠区分NAT后治疗缓解与稳定或进展疾病;本文提出的方法旨在改进放射科医生对NAT后PDAC治疗缓解的评估。

研究设计与样本

  • 叙述性综述,由AJR专家小组撰写;未报告系统检索范围、纳入文献数量或证据分级方法。

诊断标准与关键数值

  • 描述了临界可切除PDAC的当前定义及其对判断患者从NAT可能获益的意义。

临床应用与阅片要点

  • 综述探讨了影像在区分NAT后缓解与稳定或进展疾病方面的特定局限,涉及方案优化、肿瘤大小评估、血管评估和肝转移检测。
  • 考虑了MRI以及PET和/或杂交成像的作用。
  • 提供了NAT后使用的简短PDAC报告模板,旨在改进放射科医生对PDAC治疗后缓解的评估。

局限性

  • 当前影像技术无法可靠区分NAT后治疗缓解与稳定或进展疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Despite important innovations in the treatment of pancreatic ductal adenocarcinoma (PDAC), PDAC remains a disease with poor prognosis and high mortality. A key area for potential improvement in the management of PDAC, aside from earlier detection in patients with treatable disease, is the improved ability of imaging techniques to differentiate treatment response after neoadjuvant therapy (NAT) from worsening disease. It is well established that current imaging techniques cannot reliably make this distinction. This narrative review provides an update on the imaging assessment of pancreatic cancer resectability after NAT. Current definitions of borderline resectable PDAC, as well as implications for determining likely patient benefit from NAT, are described. Challenges associated with PDAC pathologic evaluation and surgical decision making that are of relevance to radiologists are discussed. Also explored are the specific limitations of imaging in differentiating the response after NAT from stable or worsening disease, including issues relating to protocol optimization, tumor size assessment, vascular assessment, and liver metastasis detection. The roles of MRI as well as PET and/or hybrid imaging are considered. Finally, a short PDAC reporting template is provided for use after NAT. The highlighted methods seek to improve radiologists' assessment of PDAC treatment response after NAT.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Soloff, Al-Hawary, Desser, et al. Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: AJR Expert Panel Narrative Review. AJR Am J Roentgenol. 2021. PMID: 34851713. doi:10.2214/AJR.21.26931

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。